Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. This evidence concerns the gene SLC5A2 and early-onset autosomal dominant Alzheimer disease.